| 000 | 01565 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515120522.0 | ||
| 264 | 0 | _c20080515 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(08)70111-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRibera, Josep-Maria | |
| 245 | 0 | 0 |
_aAdverse prognosis of bulky disease in good-risk DLBCL. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cMay 2008 |
||
| 300 |
_a406-7 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 9 _gno. 5 _gp. 406-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(08)70111-6 _zAvailable from publisher's website |
| 999 |
_c17948866 _d17948866 |
||